Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffery Zimmerman

Podiatrist Shillington, PA Doctor of Podiatric Medicine

NPI 1952822876 CMS profile 3367009

654 Philadelphia Ave, Shillington, PA 19607

Open in the dashboard

General payments

$23,826

167 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffery Zimmerman of Shillington, PA is reported in the CMS Open Payments database as having received $23,826 across 167 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,803 41
2024 General $7,787 44
2023 General $3,779 24
2022 General $2,054 23
2021 General $1,132 16
2020 General $350 6
2019 General $920 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffery Zimmerman
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Jeffery Zimmerman were reported at $7,803. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Jeffery Zimmerman Podiatrist median Middle half National median
2019 $920 $196 $72–$601 $163
2020 $350 $118 $38–$335 $114
2021 $1,132 $169 $57–$573 $132
2022 $2,054 $220 $74–$782 $149
2023 $3,779 $208 $71–$635 $160
2024 $7,787 $237 $87–$681 $164
2025 $7,803 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $9,416 24 payments
  2. Forma Medical $5,667 6 payments
  3. Stryker Corporation $3,606 51 payments
  4. Novus Surgical Consultants $1,754 19 payments
  5. Organogenesis Inc. $667 14 payments
  6. Smith+Nephew, Inc. $435 11 payments
  7. Novus Surgical Solutions LLC $244 2 payments
  8. Treace Medical Concepts, Inc. $226 4 payments
  9. Medline Industries, Inc. $210 2 payments
  10. Fortis Surgical, LLC $172 1 payment
  11. Other $1,431 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,614 146 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,500 4 payments
  3. Consulting Fee $5,417 4 payments
  4. Travel and Lodging $3,280 12 payments
  5. Entertainment $15 1 payment
Products named General payments · program years 2019–2025
  1. OptimalMTP $3,499 5 payments
  2. OptimalHT $2,168 1 payment
  3. PRIME SERIES $1,086 5 payments
  4. BIOSKIN $360 3 payments
  5. CITREFIX $270 4 payments
  6. AMNIOEXCEL $224 3 payments
  7. ORTHOLOC 3DI $211 4 payments
  8. AUGMENT INJECTABLE $182 2 payments
  9. INBONE $179 2 payments
  10. VALOR $175 1 payment
  11. Other $5,522 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

279

Median for Podiatry: 160

Drug cost

$3,150

Median for Podiatry: $2,368

Branded share of claims

18.6%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Ciclopirox Olamine Brand 26 $799
Gabapentin Generic 73 $665
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 13 $372
Ssd Silver Sulfadiazine Brand 13 $347
Cephalexin Generic 36 $326
Methylprednisolone Generic 23 $157
Meloxicam Generic 45 $146
Celecoxib Generic 19 $129
Terbinafine Hcl Generic 12 $121
Cyclobenzaprine Hcl Generic 19 $89

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$142,097

Of which drugs: $124

Medicare patients

394

Average age 77

Services billed

3,492

240 women, 154 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Diabetes 37%
Ischemic heart disease 34%
Chronic kidney disease 32%
Osteoporosis 27%
Heart failure 23%
Depression 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 36 141 $111
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 36 141 $13

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

167 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record